Table 3.
Definite COVID-19 versus probable COVID-19
| Variable | Patients with definite COVID-19, n = 55 | Patients with probable COVID-19, n = 62 | p value |
|---|---|---|---|
| Age, mean±SD, years | 51.5±17.1 | 60.3±15.2 | 0.004 |
| Sex, M/F | 28/27 | 35/26 | 0.485 |
| Ratio, % | 50.9/49.1 | 57.4/42.6 | |
| Presenting of general symptoms, n (%) | |||
| Fever | 47 (85.5) | 54 (87.1) | 0.796 |
| Sore throat | 6 (10.9) | 1 (1.6) | 0.034 |
| Fatigue and malaise | 20 (36.4) | 10 (16.1) | 0.012 |
| Headache | 21 (38.1) | 15 (24.2) | 0.102 |
| Dizziness and/or vertigo | 9 (16.4) | 4 (6.5) | 0.089 |
| GIT symptoms and signs | 11 (20) | 18 (29) | 0.259 |
| Respiratory symptoms and signs | 48 (87.3) | 52 (83.9) | 0.602 |
| CNS, n (%) | |||
| Cerebrovascular stroke | 12 (21.8) | 43 (69.4) | <0.001 |
| Convulsion | 4 (7.3) | 1 (1.6) | 0.131 |
| Encephalitis | 2 (3.6) | 4 (6.5) | 0.491 |
| Hypoxic encephalopathy | 2 (3.6) | 2 (3.2) | 0.903 |
| Cord myelopathy | 2 (3.6) | 0 | 0.130 |
| Attack of relapse of MS | 0 | 2 (3.2) | 0.179 |
| Meningoencephalitis | 1 (1.8) | 0 | 0.286 |
| PNS, n (%) | |||
| GBS | 2 (3.6) | 2 (3.2) | 0.903 |
| Peripheral neuropathy | 0 | 3 (4.8) | 0.098 |
| Myositis | 1 (1.8) | 1 (1.6) | 0.932 |
| Myasthenia | 0 | 2 (3.2) | 0.179 |
| Isolated cranial nerves (anosmia and ageusia) | 29 (52.7) | 2 (3.2) | <0.001 |
| Comorbidities, n (%) | |||
| Hypertension | 20 (36.4) | 33 (53.2) | 0.067 |
| Ischemic heart | 12 (21.8) | 16 (25.8) | 0.614 |
| Diabetes mellitus | 23 (41.8) | 18 (29.0) | 0.148 |
| Impaired liver function | 3 (5.5) | 3 (4.8) | 0.880 |
| Impaired renal function | 2 (3.6) | 8 (12.9) | 0.074 |
| Chest disease | 3 (5.5) | 1 (1.6) | 0.254 |
| Neurological disease (types) | 5 (9.1) | 9 (14.5) | 0.367 |
GIT, gastrointestinal tract; GBS, Guillain-Barré syndrome; CNS, central nervous system; PNS, peripheral nervous system; PD, Parkinson's disease; AD, Alzheimer's disease; MG, myasthenia gravis; MS, multiple sclerosis.